A phase 1/2 trial of carfilzomib + high dose melphalan conditioning for auto-HCT followed by carfilzomib maintenance for patients with relapsed multiple myeloma Meeting Abstract
| Authors: | Costa, L. J.; Landau, H.; Chhabra, S.; Hari, P.; Innis-Shelton, R.; Saad, A.; Salzman, D.; Hamadani, M.; Tamari, R.; Williams, L.; Orlando, E.; Dixon, P.; Giralt, S. A. |
| Abstract Title: | A phase 1/2 trial of carfilzomib + high dose melphalan conditioning for auto-HCT followed by carfilzomib maintenance for patients with relapsed multiple myeloma |
| Meeting Title: | 2017 BTM Tandem Meetings |
| Journal Title: | Biology of Blood and Marrow Transplantation |
| Volume: | 23 |
| Issue: | 3 Suppl. 1 |
| Meeting Dates: | 2017 Feb 22-26 |
| Meeting Location: | Orlando, FL |
| ISSN: | 1083-8791 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-03-01 |
| Start Page: | S63 |
| End Page: | S64 |
| Language: | English |
| ACCESSION: | WOS:000540635000058 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.bbmt.2016.12.038 |
| Notes: | Meeting Abstract: 61; The page number on ScienceDirect is erroneously listed as S81-S82 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work